Our study revealed the suppressive function of AMBRA1 in the NRF2‐mediated antioxidant response and the dysregulated mechanism of AMBRA1 deubiquitination in the oxidative stress response, highlighting the therapeutic potential of the targeted inhibition of AMBRA1 or USP7 for the treatment of IBD. Here, AMBRA1 is linked to inflammatory bowel disease.